50 Best Peptides

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#134

Myostatin Inhibitor Peptide

Muscle GrowthGDF-8 InhibitorMyostatin-Blocking PeptideACE-031 Analog

Peptides designed to block myostatin (GDF-8), a negative regulator of muscle growth, investigated for treating muscle-wasting conditions and enhancing muscle mass.

Share:

Overview

Myostatin inhibitor peptides are synthetic or modified peptides designed to block the activity of myostatin (also known as growth differentiation factor-8 or GDF-8), a member of the TGF-β superfamily that acts as a potent negative regulator of skeletal muscle growth. Myostatin was discovered in 1997 by Se-Jin Lee at Johns Hopkins University, when knockout mice lacking the myostatin gene developed dramatically increased muscle mass — approximately double that of normal mice.

Naturally occurring myostatin mutations have been documented in several species, including cattle (Belgian Blue and Piedmontese breeds known for extreme muscularity), dogs (whippets), and in a rare human case — a German boy born in 2004 with a myostatin mutation who showed extraordinary muscle development. These natural experiments powerfully demonstrate the potential of myostatin inhibition for muscle growth.

Several approaches to myostatin inhibition have been developed. Peptide-based strategies include myostatin propeptide fragments that bind and inactivate mature myostatin, receptor-binding domain peptides that competitively block myostatin's interaction with its receptor (ActRIIB), and modified decoy receptors. Larger biologic approaches include monoclonal antibodies (stamulumab/MYO-029, domagrozumab) and soluble receptor fusion proteins (ACE-031, ramatercept). The peptide-based approaches offer potential advantages in terms of manufacturing and delivery.

Clinical development has targeted muscle-wasting conditions including muscular dystrophy, sarcopenia (age-related muscle loss), cachexia, and disuse atrophy. While preclinical results have been consistently impressive, clinical translation has been challenging. Some programs have been discontinued due to safety signals (ACE-031 was halted due to nosebleeds and gum bleeding, likely related to effects on vascular remodeling). Nevertheless, the myostatin pathway remains one of the most actively pursued targets for muscle-wasting diseases.

Research Uses & Applications

  • Investigated for muscular dystrophy treatment (Duchenne, facioscapulohumeral, and others)
  • Research into treatment of age-related sarcopenia and muscle wasting
  • Explored for cancer-associated cachexia and muscle loss prevention
  • Studied for improving muscle recovery after immobilization or surgery
  • Performance enhancement interest in bodybuilding communities (unapproved use)
  • Research into metabolic benefits of increased muscle mass

Key Research Findings

  • Myostatin knockout mice showed approximately 100% increase in skeletal muscle mass, establishing myostatin as the most potent known negative regulator of muscle growth (McPherron et al., Nature, 1997).
  • Clinical trials of stamulumab (anti-myostatin antibody) showed modest improvements in muscle strength in adult muscular dystrophy but did not meet primary endpoints.
  • ACE-031 (soluble ActRIIB-Fc) increased lean body mass in boys with Duchenne muscular dystrophy but was discontinued due to vascular adverse events.
  • Preclinical studies showed myostatin propeptide administration increased muscle mass and improved metabolic parameters in aged mice.
  • Research demonstrated that myostatin inhibition not only increases muscle mass but also reduces fat mass and improves insulin sensitivity in animal models.

Risks & Side Effects

  • No myostatin inhibitor peptide is approved for clinical use; all remain investigational.
  • Vascular adverse events observed with broad ActRIIB inhibition (ACE-031 safety signals).
  • Potential for unintended effects on other TGF-β family members when using broad pathway inhibitors.
  • Tendon and ligament adaptation may not keep pace with rapid muscle hypertrophy.
  • Cardiac effects of myostatin inhibition are not fully understood, as myostatin is also expressed in heart tissue.
  • Products sold as myostatin inhibitors in the supplement market are of unverified quality and efficacy.

Administration

Investigational peptide-based myostatin inhibitors have been studied via subcutaneous injection at various doses in preclinical and clinical studies. Biologic approaches (antibodies, fusion proteins) are administered IV or subcutaneously at doses specific to each compound. No approved dosing protocols exist. Supplement products claiming myostatin inhibition are available orally but lack validated efficacy data.

Legal Status

Myostatin inhibitor peptides are available as research chemicals. No myostatin inhibitor is FDA-approved for any indication. Clinical trials for various myostatin inhibition approaches are ongoing. Myostatin inhibition-related products are banned by WADA. Not controlled substances, but unapproved for human therapeutic use.

Frequently Asked Questions

What is Myostatin Inhibitor Peptide?

Peptides designed to block myostatin (GDF-8), a negative regulator of muscle growth, investigated for treating muscle-wasting conditions and enhancing muscle mass.

What are the main uses of Myostatin Inhibitor Peptide?

The primary research applications of Myostatin Inhibitor Peptide include: Investigated for muscular dystrophy treatment (Duchenne, facioscapulohumeral, and others); Research into treatment of age-related sarcopenia and muscle wasting; Explored for cancer-associated cachexia and muscle loss prevention; Studied for improving muscle recovery after immobilization or surgery; Performance enhancement interest in bodybuilding communities (unapproved use); Research into metabolic benefits of increased muscle mass.

What are the risks and side effects of Myostatin Inhibitor Peptide?

Documented risks and side effects include: No myostatin inhibitor peptide is approved for clinical use; all remain investigational.; Vascular adverse events observed with broad ActRIIB inhibition (ACE-031 safety signals).; Potential for unintended effects on other TGF-β family members when using broad pathway inhibitors.; Tendon and ligament adaptation may not keep pace with rapid muscle hypertrophy.; Cardiac effects of myostatin inhibition are not fully understood, as myostatin is also expressed in heart tissue.; Products sold as myostatin inhibitors in the supplement market are of unverified quality and efficacy.. Always consult a healthcare professional before considering any peptide.

Is Myostatin Inhibitor Peptide legal?

Myostatin inhibitor peptides are available as research chemicals. No myostatin inhibitor is FDA-approved for any indication. Clinical trials for various myostatin inhibition approaches are ongoing. Myostatin inhibition-related products are banned by WADA. Not controlled substances, but unapproved for human therapeutic use.

How is Myostatin Inhibitor Peptide administered?

Investigational peptide-based myostatin inhibitors have been studied via subcutaneous injection at various doses in preclinical and clinical studies. Biologic approaches (antibodies, fusion proteins) are administered IV or subcutaneously at doses specific to each compound. No approved dosing protocols exist. Supplement products claiming myostatin inhibition are available orally but lack validated efficacy data.

Related Peptides

#24

MGF

Muscle Growth

#25

IGF-1 LR3

Muscle Growth

#26

Follistatin 344

Muscle Growth

#47

ACE-031

Muscle Growth

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Official Store

Experience Peptides on Your Skin

Shop our curated collection of peptide-infused skincare — Copper Peptide serums, anti-aging treatments, hydrogel patches, and more.

Shop Peptide Skincare

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.

← #133 Irisin#135 Follistatin 315 →